XB130 is overexpressed in prostate cancer and involved in cell growth and invasion.
XB130 is overexpressed in prostate cancer and involved in cell growth and invasion.
复制标题
DOI：
10.18632/oncotarget.11074
复制
发表时间：
2016-09-13
期刊：
影响因子：
--
通讯作者：
Liu J
中科院分区：
文献类型：
--
作者：
Chen B;Liao M;Wei Q;Liu F;Zeng Q;Wang W;Liu J;Hou J;Yu X;Liu J
XB 130是一种细胞溶质衔接蛋白，参与多种生理过程和某些恶性肿瘤的发生，但其在前列腺癌发生中的作用尚不清楚。本研究检测了前列腺癌组织中XB 130的表达，发现XB 130在前列腺癌组织中的表达显著升高，并与前列腺特异性抗原（PSA）、游离PSA（f-PSA）、前列腺酸性磷酸酶（PAP）和T分级显著相关。XB 130高表达的患者生存率显著降低，这表明XB 130可能是前列腺癌的预后指标。体外实验表明，降低XB 130表达抑制肿瘤生长在体外和体内。此外，XB 130敲低阻碍前列腺癌细胞系DU 145和LNCap的G1向S期的转变，这可能有助于抑制细胞增殖。transwell实验结果表明，下调XB 130表达可抑制前列腺癌的侵袭和转移。Western blot半定量分析表明，随着Akt信号转导和EMT过程的减少，XB 130表达减少。因此，上述观察表明，XB 130可能是一种新的前列腺癌分子标志物和有效的治疗靶点。
XB130 is a cytosolic adaptor protein involved in various physiological processes and oncogenesis of certain malignancies, but its role in the development of prostate cancer remains unclear. In current study, we examined XB130 expression in prostate cancer tissues and found that XB130 expression was remarkably increased in prostate cancer tissues and significantly correlated with increased prostate specific antigen (PSA), free PSA (f-PSA), prostatic acid phosphatase (PAP) and T classification. Patients with highly expressed XB130 had significantly decreased survival, which suggested XB130 as a possible prognostic indicator for prostate cancer. In vitro experiments showed that reduced XB130 expression restrained tumor growth both in vitro and in vivo. Furthermore, XB130 knockdown hindered transition of G1 to S phase in prostate cancer cell line DU145 and LNCap, which might contribute to the inhibition of cellular proliferation. Results from transwell assay demonstrated that downregulation of XB130 may attenuate invasion and metastasis of prostate cancer. Semiquantitative analysis of Western blot suggested that decreased XB130 expression was accompanied by diminished Akt signaling and EMT process. Thus, above observations suggest that XB130 may be a novel molecular marker and potent therapeutic target for prostate cancer.